160 related articles for article (PubMed ID: 33441356)
1. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system.
Galeone C; Bruzzi P; Jommi C
BMJ Open; 2021 Jan; 11(1):e041259. PubMed ID: 33441356
[TBL] [Abstract][Full Text] [Related]
2. The Evaluation of Drug Innovativeness in Italy: Key Determinants and Internal Consistency.
Jommi C; Galeone C
Pharmacoecon Open; 2023 May; 7(3):373-381. PubMed ID: 36763319
[TBL] [Abstract][Full Text] [Related]
3. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
4. Using GRADE methodology to assess innovation of new medicinal products in Italy.
Fortinguerra F; Tafuri G; Trotta F; Addis A
Br J Clin Pharmacol; 2020 Jan; 86(1):93-105. PubMed ID: 31656055
[TBL] [Abstract][Full Text] [Related]
5. The Assessment of the Innovativeness of a New Medicine in Italy.
Fortinguerra F; Perna S; Marini R; Dell'Utri A; Trapanese M; Trotta F;
Front Med (Lausanne); 2021; 8():793640. PubMed ID: 34957163
[No Abstract] [Full Text] [Related]
6. [Innovative medicinal products: the new criteria of the Italian Medicines Agency.].
Mammarella F; Tafuri G
Recenti Prog Med; 2018 May; 109(5):261-262. PubMed ID: 29771247
[TBL] [Abstract][Full Text] [Related]
7. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
8. Do France, Germany, and Italy agree on the added therapeutic value of medicines?
Casilli G; Lidonnici D; Jommi C; De Nigris M; Genazzani AA
Int J Technol Assess Health Care; 2023 Aug; 39(1):e54. PubMed ID: 37580971
[TBL] [Abstract][Full Text] [Related]
9. Skip pattern approach toward the early access of innovative anticancer drugs.
Apolone G; Ardizzoni A; Biondi A; Bortolami A; Cardone C; Ciniselli CM; Conte P; Crippa C; de Braud F; Duca M; Gori S; Gritti G; Inno A; Luksch R; Lussana F; Maio M; Pasello G; Perrone F; Rambaldi A; Rossi G; Signorelli D; Soverini G; Valente M; Verderio P; Buzzetti G
ESMO Open; 2021 Aug; 6(4):100227. PubMed ID: 34352703
[TBL] [Abstract][Full Text] [Related]
10. Leveraging EUnetHTA's conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer's point of view.
Giuliani G; Chassagnol F; Traub D; Gyldmark M; Hebborn A; Ducournau P; Ruof J
Health Econ Rev; 2018 Sep; 8(1):24. PubMed ID: 30242522
[TBL] [Abstract][Full Text] [Related]
11. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
12. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical innovativeness index: methodological approach for assessing the value of medicines - a case study of oncology drugs.
Gargano LP; Alvares-Teodoro J; de A Acurcio F; Guerra AA
Expert Rev Pharmacoecon Outcomes Res; 2024 Jun; ():1-10. PubMed ID: 38859799
[TBL] [Abstract][Full Text] [Related]
14. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
15. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
16. Do patients value a hospital's innovativeness reputation? A multi-method approach to assess the relative importance of innovativeness reputation in patients' hospital choice.
Gurtner S; Hietschold N; Vaquero MartÃn M
Health Serv Manage Res; 2018 Aug; 31(3):138-153. PubMed ID: 29277121
[TBL] [Abstract][Full Text] [Related]
17. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.
Russo P; Mennini FS; Siviero PD; Rasi G
Ann Oncol; 2010 Oct; 21(10):2081-2087. PubMed ID: 20335370
[TBL] [Abstract][Full Text] [Related]
18. Hospital innovativeness and organizational performance: evidence from English public acute care.
Salge TO; Vera A
Health Care Manage Rev; 2009; 34(1):54-67. PubMed ID: 19104264
[TBL] [Abstract][Full Text] [Related]
19. New requirements for phase I trials: a challenge for Italian clinical research.
Marchesi E; Monti M; Nanni O; Bassi L; Piccinni-Leopardi M; Cagnazzo C
Tumori; 2018; 104(1):15-21. PubMed ID: 28799641
[TBL] [Abstract][Full Text] [Related]
20. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.
Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S
Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
